newsfilter
← Latest News
ACCESS Newswire·

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

Cash expected to fund operations into the second half of 2026Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme HOUSTON,